Navitoclax (ABT-263)

Catalog No.S1001

Navitoclax (ABT-263) Chemical Structure

Molecular Weight(MW): 974.61

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 400 In stock
USD 120 In stock
USD 200 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 37 Publications

13 Customer Reviews

  • KP cells (A) and A549 cells (B) were treated with increasing doses of ATN-224 alone or with the BCL2 inhibitor ABT-263, and cell death (96 hours) was determined.

    J Clin Invest, 2014, 124(1): 117-28 . Navitoclax (ABT-263) purchased from Selleck.

    Cell lines are also resistant to dual inhibition of Bcl-xL and Bcl-2 by the inhibitor ABT-263 when dosed with NSC siRNA, but co-dosing ABT-263 with Mcl-1 siRNA decreases compound IC50 similar to that observed with WEHI-539. Representative curves for MDA-MB-157 are shown in f.

    Cell Death Differ, 2015, 10.1038/cdd.2015.73. Navitoclax (ABT-263) purchased from Selleck.

  • ABT-263 has a higher albumin binding affinity than ABT-737. The binding capacity of ABT-737 (solid lines) and ABT-263 (dotted lines) to HSA was investigated using a fluorescence polarization assay. A, to measure binding to site 2 on HSA-IIIA, dansyl sarcosine was used as a probe. In this assay the IC50 was 711 and 37μmol/L for ABT-737 and ABT-263, respectively. B, to measure binding to site 1 on HSA-IIA, dansyl L-glutamate was used as a probe. The IC50 was >1,000 and 145 μmol/L for ABT-737 and ABT-263, respectively.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2011 408(2), 344-9. Navitoclax (ABT-263) purchased from Selleck.

     

    (A) In vitro generated  Mcl-1-deleted  Arf-/- p185+ cells stably expressing the indicated constructs were treated with indicated doses of navitoclax (ABT-263) for 24 hours after which percent viable cells were determined (propidium iodide negative cells were scored as viable). Each point represents the average of three independent experiments and the error bars denote the SEM.  p185+ Arf-/- cells serve as a control.  (B) Arf -null p185+ cells were treated with navitoclax for 24 hours at indicated doses. Lysates were immunoprecipitated with anti-BIM antibody and immune complexes were resolved and western blotted for MCL-1, BCL-2 (human specific antibody), BCL-XL, BIM, PARP and Actin (loading control). Endogenous BIM serves as the control for equal immunoprecipitation. (E&F) p185+ Arf-/- cells were treated with indicated doses of navitoclax and/or  (E) IM or  (F) DAS for 24 hours after which percent viable cells was determined. Annexin-V and PI negative cells were scored as viable. IL-7 was added to a final concentration of 20 ng/mL.

    Navitoclax (ABT-263) purchased from Selleck.

  •  

    Human Ph+ cell lines:  (A)  OP-1 Ph+ B-ALL  (B) TOM1 Ph+ B-ALL and (C)  BV173 Ph+CML blast crisis cell lines were treated with navitoclax, imatinib (IM) or dasatinib (DAS) at indicated doses for 24 hours after which cell lysates were analyzed for expression of MCL-1, BCL-2, BCL-w, BFL-1 and BCL-XL.  For potentiation experiments, the percentage of viable cells was determined by Annexin-V and PI negativity.

    Navitoclax (ABT-263) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Targets
Bcl-xL [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
A1 [1]
(Cell-free assay)
Mcl-1 [1]
(Cell-free assay)
<=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki) 354 nM(Ki) 550 nM(Ki)
In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell NHr4NpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nCWWlEPTB;MD6wNFY3QSEQvF2= NIWzR4pUSU6JRWK=
MV-4-11 MnHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTBwMEG1PFYh|ryP NIn0U3BUSU6JRWK=
NKM-1 NHjtSIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPjTWM2OD1yLkCxOlk6KM7:TR?= M1HSWXNCVkeHUh?=
ML-2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHmTVRtUUN3ME2wMlAyQTh|IN88US=> NF;uVXlUSU6JRWK=
BV-173 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoL4TWM2OD1yLkCyN|E1KM7:TR?= MlToV2FPT0WU
RS4-11 MkjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjHO5BKSzVyPUCuNFI2QDdizszN NEHlR|RUSU6JRWK=
HL-60 NULCV|RGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlS5TWM2OD1yLkCyPVA5KM7:TR?= Mn;6V2FPT0WU
KY821 M2nQd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7yTWM2OD1yLkCyPVc2KM7:TR?= MoHiV2FPT0WU
ECC10 NFeyfXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTBwMEO3PVIh|ryP MYfTRW5ITVJ?
NCI-H720 M1\zZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvvZ4tOUUN3ME2wMlA1ODFzIN88US=> MUHTRW5ITVJ?
QIMR-WIL NH\nVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzBTWM2OD1yLkC0Nlg4KM7:TR?= NXfkO5NkW0GQR1XS
KG-1 M4jqZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHLNYJKSzVyPUCuNFQ1QDZizszN MV7TRW5ITVJ?
TGW M3nxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTBwMES2N|Mh|ryP MnTpV2FPT0WU
ATN-1 MoHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTBwMES3N|Mh|ryP NIK2bYhUSU6JRWK=
RH-18 MmLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTTTWM2OD1yLkC2NFQ5KM7:TR?= NH\BRVdUSU6JRWK=
EW-18 MoKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHqUYF7UUN3ME2wMlA3QDRzIN88US=> M2rIXnNCVkeHUh?=
NB17 M1G2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwMEexNlQh|ryP NIfTU2lUSU6JRWK=
SK-NEP-1 NXvVRVU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLqTWM2OD1yLkC3NlE{KM7:TR?= Mnj3V2FPT0WU
P12-ICHIKAWA MlzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\1eGlEPTB;MD6wO|c4QCEQvF2= MmnYV2FPT0WU
KARPAS-45 NHzWOIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPnT41KSzVyPUCuNFc5OTVizszN NEXTbJlUSU6JRWK=
EW-3 Mo\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLld|dKSzVyPUCuNFgxPTNizszN M4rXOnNCVkeHUh?=
NB13 NHrVOI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPQVXc2UUN3ME2wMlA5OjB|IN88US=> Ml\jV2FPT0WU
NCI-H209 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDzTWM2OD1yLkC4O|A1KM7:TR?= NWKxPWpHW0GQR1XS
NCI-H1092 NXzabohTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{ixUGlEPTB;MD6xNFI4PSEQvF2= MYjTRW5ITVJ?
NH-12 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTBwMUC3OFQh|ryP MUXTRW5ITVJ?
697 M13Dd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGS1UI1KSzVyPUCuNVA5OzlizszN M2[1c3NCVkeHUh?=
KE-37 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\5cmlEPTB;MD6xNVM4KM7:TR?= MVrTRW5ITVJ?
MOLT-4 M3fNPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTBwMUWxOlkh|ryP M33jfHNCVkeHUh?=
CHP-134 MoLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTBwMU[zNFYh|ryP M3PreHNCVkeHUh?=
D-283MED M1qzZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwMUe2PFYh|ryP Mk\lV2FPT0WU
LU-135 NU\s[IRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HlPWlEPTB;MD6xPFU2OiEQvF2= MYfTRW5ITVJ?
LU-134-A M2f0[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWS1NJQ{UUN3ME2wMlE5PjdzIN88US=> NXPncFd[W0GQR1XS
EM-2 NHPoNmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;abZFKSzVyPUCuNVk6OThizszN Mm\oV2FPT0WU
LU-139 M4fib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\MTWM2OD1yLkKwOFk5KM7:TR?= NEHEVohUSU6JRWK=
ALL-PO NEHIZZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTBwMkG5PFgh|ryP MVvTRW5ITVJ?
NB12 NIH1TpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jJU2lEPTB;MD6yN|EyPSEQvF2= MlTmV2FPT0WU
KP-N-YN MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDHeGVTUUN3ME2wMlI{PTd|IN88US=> NF;OSm9USU6JRWK=
BEN NUjSbWE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHv6WZlKSzVyPUCuNlM6PjhizszN MUXTRW5ITVJ?
HCC1569 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwMkWxNFYh|ryP NXHTU2M5W0GQR1XS
HuO9 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfWUWtKSzVyPUCuNlY4OTVizszN M{jMPXNCVkeHUh?=
WM-115 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1X6XmlEPTB;MD6yO|c{QCEQvF2= MkXXV2FPT0WU
CCRF-CEM NGK2UnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfKN45bUUN3ME2wMlM{PTJ7IN88US=> MWjTRW5ITVJ?
IST-SL1 NF\iNXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTPPGFKSzVyPUCuN|U{PDNizszN NVKx[XNNW0GQR1XS
BE-13 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\VOpdKSzVyPUCuN|Y1PTlizszN M{\PcHNCVkeHUh?=
COR-L88 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwM{[1OEDPxE1? M2\mR3NCVkeHUh?=
DOHH-2 NFm0O|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[4TWM2OD1yLkSxNFI{KM7:TR?= M{nmS3NCVkeHUh?=
A704 MlLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwNEK2O{DPxE1? Mm\nV2FPT0WU
KNS-81-FD M{XNb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXpTWM2OD1yLkS0NFE4KM7:TR?= MkDIV2FPT0WU
RPMI-8226 M1PGdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;pTWM2OD1yLkS1OlUzKM7:TR?= MUnTRW5ITVJ?
TGBC24TKB NIPme2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTBwNEW3O|gh|ryP NUHZc216W0GQR1XS
NCI-H1304 NGDydVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37lSmlEPTB;MD60OlE2PyEQvF2= M2Duc3NCVkeHUh?=
MOLT-13 M1mxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwNE[2NVMh|ryP M4njfHNCVkeHUh?=
EW-22 NWjpcZpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1m0R2lEPTB;MD60OlY4OSEQvF2= NHS4[ZhUSU6JRWK=
MS-1 NYfkRo9ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzEd2J3UUN3ME2wMlQ3QTN|IN88US=> MYLTRW5ITVJ?
RMG-I MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmOwTWM2OD1yLkS5OFY1KM7:TR?= NVv5UGhvW0GQR1XS
NTERA-S-cl-D1 NIe1TFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3GzOGlEPTB;MD61NFAyQSEQvF2= M1rG[HNCVkeHUh?=
NCI-H1048 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PIVGlEPTB;MD61NFk2OyEQvF2= MWjTRW5ITVJ?
SW1417 NXTCR3RKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjx[nJbUUN3ME2wMlU2PDN6IN88US=> M{fZd3NCVkeHUh?=
DB NX7NeIs{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fRbGlEPTB;MD61O|A5KM7:TR?= MmX0V2FPT0WU
MEG-01 NX;XUpZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTkTWM2OD1yLkW4N|Ih|ryP MmrPV2FPT0WU
EW-13 NUXTcGVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPWPGdKSzVyPUCuOVg{PDFizszN NV32PW4{W0GQR1XS
LAMA-84 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmmxTWM2OD1yLkW5NlA4KM7:TR?= NEn4cItUSU6JRWK=
J-RT3-T3-5 M{nDNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlr6TWM2OD1yLk[wPFA5KM7:TR?= M4HQSXNCVkeHUh?=
MOLT-16 M3PPZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlO5TWM2OD1yLk[1NlY1KM7:TR?= MkXBV2FPT0WU
DU-4475 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwNkW0Nlch|ryP MXfTRW5ITVJ?
HAL-01 Mlr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwN{K1OFkh|ryP M33JUnNCVkeHUh?=
RD NGPqWVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;mdmJRUUN3ME2wMlc2QDl7IN88US=> MmjwV2FPT0WU
OAW-28 NInJcFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;MdWlEPTB;MD63PFM4KM7:TR?= M3G5O3NCVkeHUh?=
HCC38 NW\pZVNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTBwOECxPUDPxE1? NHHnZ2RUSU6JRWK=
NMC-G1 M4LoOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XNcmlEPTB;MD64NVEzOSEQvF2= NU\ZbWkzW0GQR1XS
EW-16 NXjLWmxET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDUTWhKSzVyPUCuPFE{OjhizszN MXfTRW5ITVJ?
DU-145 MojpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITkRVRKSzVyPUCuPFk6OjNizszN NX\HS|hDW0GQR1XS
HPAF-II NEPBOGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnadXFKSzVyPUCuPVI3OjhizszN MlXiV2FPT0WU
A427 NWXxO4JwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXG4T5M2UUN3ME2wMlk{ODJ{IN88US=> MnzQV2FPT0WU
PA-1 MmriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jWbGlEPTB;MD65OVY1OiEQvF2= MmP3V2FPT0WU
OAW-42 M4DCeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rrV2lEPTB;MD65OlE1PiEQvF2= M1vj[XNCVkeHUh?=
L-428 NIW3emtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnyzTWM2OD1zLkCxNlUh|ryP MV3TRW5ITVJ?
COLO-824 NUDMPIdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIj0UodKSzVyPUGuNFE4ODhizszN MnO0V2FPT0WU
P30-OHK M2m1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTPSZJvUUN3ME2xMlA1Pjh6IN88US=> MlryV2FPT0WU
NCI-H2170 NUTNXY1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTFwME[yN{DPxE1? MUDTRW5ITVJ?
HCC2998 NX[yenpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnVbHNPUUN3ME2xMlA4OTN3IN88US=> NVHjOZBbW0GQR1XS
NB14 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIexemNKSzVyPUGuNVM4PDhizszN NWTocIM4W0GQR1XS
TGBC1TKB MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjWTWJKSzVyPUGuNVQyPTJizszN MmTaV2FPT0WU
KP-N-YS MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XobGlEPTB;MT6xOlI{PiEQvF2= MkfZV2FPT0WU
CAL-120 M{m4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXOxZlFzUUN3ME2xMlE3PDJ7IN88US=> M1jFR3NCVkeHUh?=
SBC-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjhOnNKSzVyPUGuNVkxPTNizszN MWPTRW5ITVJ?
C32 MnjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTFwMUmwPFgh|ryP Mn;mV2FPT0WU
HCC2157 MkHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTFwMUm0PVQh|ryP NYjLNHBzW0GQR1XS
COLO-792 M4WzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHnSWh1UUN3ME2xMlIxODdzIN88US=> MX7TRW5ITVJ?
ES7 M1TyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjFOIhjUUN3ME2xMlI4QTVzIN88US=> NEHrTIZUSU6JRWK=
HEL MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjrcldKSzVyPUGuN|ExOjlizszN MV7TRW5ITVJ?
ES4 MmfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vPW2lEPTB;MT6zOFk6QCEQvF2= NU\McndkW0GQR1XS
NCI-SNU-1 Mnj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTFwM{[1OVUh|ryP NYiyd4d1W0GQR1XS
MDA-MB-415 NVznd2ZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUW2V2RYUUN3ME2xMlM5QDVizszN NXWwNXFRW0GQR1XS
NCI-H2342 MlzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTFwNECyOlkh|ryP Mn\KV2FPT0WU
NB69 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XIO2lEPTB;MT60OlI4OSEQvF2= NGjFSoFUSU6JRWK=
D-247MG M2LGUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjGTWM2OD1zLkWxNVIzKM7:TR?= M2L0d3NCVkeHUh?=
SCC-4 NFGwdZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\2TWM2OD1zLkW5PFg4KM7:TR?= MojCV2FPT0WU
HuH-7 M1vzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHkRmlWUUN3ME2xMlY4Ojl|IN88US=> NV\hTHlCW0GQR1XS
A388 M{HqNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzUTWM2OD1zLk[4O|I1KM7:TR?= NGf0blVUSU6JRWK=
Calu-3 NGHpbYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLqTWM2OD1zLkewOlk4KM7:TR?= NFyzSpJUSU6JRWK=
NCI-H1648 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTFwN{G0NVgh|ryP NVqwSlFOW0GQR1XS
NCI-H2052 MmLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjpTWM2OD1zLkeyNlAyKM7:TR?= MWDTRW5ITVJ?
Ramos-2G6-4C10 MmDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmWxTWM2OD1zLkezOlU3KM7:TR?= M4rY[nNCVkeHUh?=
DEL MoS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULWPVNSUUN3ME2xMlc1Pjl{IN88US=> NWXPUphmW0GQR1XS
SNU-423 MmrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfiTWM2OD1zLke4NVU4KM7:TR?= MoO1V2FPT0WU
COR-L23 NXHQ[I91T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7uV25QUUN3ME2xMlc6QDd2IN88US=> MomwV2FPT0WU
OMC-1 NEWwUIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTFwOE[wNVYh|ryP MYrTRW5ITVJ?
EW-11 NXzW[VhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTFwOUW2OVch|ryP MWPTRW5ITVJ?
HSC-3 NWPkNIliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\XTGlEPTB;MT65OlM3PSEQvF2= MXzTRW5ITVJ?
MLMA M4nRb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jVbmlEPTB;MT65OlY4PyEQvF2= MVrTRW5ITVJ?
RCM-1 NVfjW25CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHzTWM2OD1{LkCwN|k6KM7:TR?= MYjTRW5ITVJ?
MFE-280 M{HxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHnNJBRUUN3ME2yMlAzQDR6IN88US=> M2PT[3NCVkeHUh?=
ES8 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rvSmlEPTB;Mj6yOVQ4OSEQvF2= Mlj3V2FPT0WU
TE-11 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTJwMkm0O|Mh|ryP MkfCV2FPT0WU
HuO-3N1 NUPZNmkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnz6TWM2OD1{LkS4O|gh|ryP MmmzV2FPT0WU
MHH-NB-11 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDLTWM2OD1{LkWxNVU5KM7:TR?= NVPoOGdlW0GQR1XS
TGBC11TKB MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmK2TWM2OD1{LkW3OlgyKM7:TR?= Mo\tV2FPT0WU
HOP-92 NITtWHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\tdXpKSzVyPUKuOVg4PDNizszN MnX2V2FPT0WU
IGR-1 M3vIT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTJwNkKwN|Uh|ryP MXPTRW5ITVJ?
GOTO NYLQcZRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mor2TWM2OD1{Lk[1N|c4KM7:TR?= NGjabWZUSU6JRWK=
NCI-H1650 M3TWWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDmOGFQUUN3ME2yMlczOjF3IN88US=> NIDpcoRUSU6JRWK=
NCI-H1581 M1rSVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTJwN{m2PFEh|ryP NEjxfotUSU6JRWK=
NCI-H2405 NVHQ[Ic2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTJwOEK3PFIh|ryP NXm4TFhZW0GQR1XS
U-118-MG NV:zXXpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWX5dnNXUUN3ME2yMlk3PDlzIN88US=> NVjSV2hbW0GQR1XS
DoTc2-4510 NVzXcZdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVn4[4FRUUN3ME2zMlAyPDF5IN88US=> M2\HO3NCVkeHUh?=
NCI-H596 NWTRUGVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTNwMES5PVch|ryP M1fyVnNCVkeHUh?=
MPP-89 M3fJe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrpSIhKSzVyPUOuNFU3PjZizszN NVm2PJc2W0GQR1XS
GCIY MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XZeGlEPTB;Mz6yNFQ6OSEQvF2= NGHFTJZUSU6JRWK=
SW626 NGPSRWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1OxNmlEPTB;Mz6yOFU1OyEQvF2= NVnsWmdXW0GQR1XS
OCI-AML2 NVvDcnFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTNwM{GyO|Ih|ryP MkPsV2FPT0WU
NBsusSR M1L6O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;Yd|FGUUN3ME2zMlM1QTN6IN88US=> M4rCUXNCVkeHUh?=
AN3-CA NHjHTlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmm1TWM2OD1|LkS0NlM5KM7:TR?= M2fIPXNCVkeHUh?=
EFM-19 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTNwNEizN|kh|ryP MVfTRW5ITVJ?
RVH-421 MofGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljXTWM2OD1|LkW2PFc4KM7:TR?= NV;aeZJtW0GQR1XS
5637 NIXQfZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlL5TWM2OD1|Lk[xNVA{KM7:TR?= NE\xeJBUSU6JRWK=
PANC-08-13 M2\ufmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLQNGpsUUN3ME2zMlY{PDd{IN88US=> M{DG[3NCVkeHUh?=
H9 NETXSnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\MTWM2OD1|Lk[3NVQ1KM7:TR?= MmjYV2FPT0WU
KARPAS-299 NFftN|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTyfWF2UUN3ME2zMlY4OzZzIN88US=> MXfTRW5ITVJ?
TE-5 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXlcWQyUUN3ME2zMlcxPzB7IN88US=> NVXS[ZpbW0GQR1XS
NOS-1 M4LRXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{W1NWlEPTB;Mz63PVg{PCEQvF2= MV7TRW5ITVJ?
HH NGn2ZpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXtN5dKSzVyPUOuPFM5PjhizszN MXrTRW5ITVJ?
769-P M3vDVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPiXpBKSzVyPUOuPFk2OSEQvF2= NIm3NpNUSU6JRWK=
CHP-212 MkLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljvTWM2OD1|LkmyOVQ6KM7:TR?= M2P2OnNCVkeHUh?=
NCI-H82 MlXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7QPWtKSzVyPUOuPVU6OzZizszN MV\TRW5ITVJ?
Mo-T M2nOfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELCNHlKSzVyPUSuNFQ{OTJizszN MYnTRW5ITVJ?
BB65-RCC MmXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTRwMESzPVkh|ryP MXPTRW5ITVJ?
SW1990 NYfpcnRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jyPWlEPTB;ND6wOVkxQCEQvF2= MWrTRW5ITVJ?
LK-2 M175TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rPOmlEPTB;ND6xNVI6OyEQvF2= M2T4cnNCVkeHUh?=
ES5 NFfKSXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHz3eItKSzVyPUSuNVM6QDVizszN NGqzeWhUSU6JRWK=
JVM-3 NEXVZ|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPXcVVoUUN3ME20MlE5OjJ{IN88US=> MU\TRW5ITVJ?
RPMI-7951 M17JbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jVcmlEPTB;ND6yNlQyOyEQvF2= M4iwVHNCVkeHUh?=
Calu-6 Mk\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXmwOlVlUUN3ME20MlI4QDhzIN88US=> MnjWV2FPT0WU
LC-2-ad MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTRwMkm1Olgh|ryP MV;TRW5ITVJ?
SW954 MoDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXvTWM2OD12LkK5OlYh|ryP M{DaW3NCVkeHUh?=
H-EMC-SS NUHaUXo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXkTWM2OD12LkOxPFMyKM7:TR?= MVzTRW5ITVJ?
ES3 NYX3S5VJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonHTWM2OD12LkO1OFQyKM7:TR?= M1:zVHNCVkeHUh?=
no-11 M3G3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmT4TWM2OD12LkO1OVU1KM7:TR?= NYfzNHRTW0GQR1XS
LAN-6 MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnq1TWM2OD12LkS1NVg6KM7:TR?= NEnaNI9USU6JRWK=
FTC-133 NYPOUpBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjNR482UUN3ME20MlU{QTVizszN NUHFTHhRW0GQR1XS
8505C M{nNN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoqwTWM2OD12LkW0NlMh|ryP MYHTRW5ITVJ?
SW620 NUHPSW5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnoTmVKSzVyPUSuOVcxPTdizszN NGnwRpNUSU6JRWK=
BCPAP NF;DSGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrkTWM2OD12Lk[zOFgyKM7:TR?= MV3TRW5ITVJ?
SK-LU-1 NH3IbWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDJb5NmUUN3ME20MlY3ODh7IN88US=> NGDTV4pUSU6JRWK=
NCI-H1623 MnHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTRwN{CyNlgh|ryP M2CybXNCVkeHUh?=
C2BBe1 M362cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTRwN{SwNFgh|ryP Ml7IV2FPT0WU
GP5d MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\XTWM2OD12Lke4N|g5KM7:TR?= NULpdnhEW0GQR1XS
NB6 NXTGPGpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnLTWM2OD12Lki2NlA1KM7:TR?= M37IVHNCVkeHUh?=
MDA-MB-157 NFHZPJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3mXXFKSzVyPUSuPFg4PiEQvF2= M4jjNHNCVkeHUh?=
UMC-11 NFTOXHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnE[pk4UUN3ME20Mlg5QTZ2IN88US=> NXu3bYdCW0GQR1XS
HCC1419 M4HSbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1riOWlEPTB;ND65NFA3OyEQvF2= NVn2eGdJW0GQR1XS
NCI-H2029 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fRRWlEPTB;ND65OFE5PSEQvF2= NFi5c5FUSU6JRWK=
LXF-289 NEnSOItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrLb5lrUUN3ME21MlA{PzF7IN88US=> MWXTRW5ITVJ?
KINGS-1 MnPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTVwMEe3OFQh|ryP MXHTRW5ITVJ?
HD-MY-Z MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTVwMkO5Olkh|ryP NVLKeXNMW0GQR1XS
ESS-1 MofVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnsTWxHUUN3ME21MlI2PTl5IN88US=> M332[XNCVkeHUh?=
GI-1 M{TkUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTVwMke5NlYh|ryP NFrsSlJUSU6JRWK=
RPMI-2650 NX;5TXU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTVwM{[xOkDPxE1? Moj4V2FPT0WU
IA-LM NVr3bGN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTVwM{m4O|Eh|ryP NI\k[JdUSU6JRWK=
KP-4 NHLa[pdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfOVmx{UUN3ME21MlQ3OzN2IN88US=> MmnDV2FPT0WU
G-402 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\QZmlEPTB;NT61NVg3PSEQvF2= MYnTRW5ITVJ?
OS-RC-2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDRWpNKSzVyPUWuOVI3ODRizszN M2KxOHNCVkeHUh?=
NCI-H1155 M3P1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTVwNUS5OVUh|ryP NV;ofoNlW0GQR1XS
OE19 NXLld|g3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\tTWM2OD13Lk[4OlI1KM7:TR?= MoLwV2FPT0WU
U-2-OS NGXoTZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVThPG4xUUN3ME21Mlg6ODF|IN88US=> M1fnZ3NCVkeHUh?=
SCC-15 Mk\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTVwOUO2OlIh|ryP MX7TRW5ITVJ?
NCI-H630 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fL[WlEPTB;NT65PVQxPCEQvF2= M2m2OnNCVkeHUh?=
PFSK-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fLeWlEPTB;Nj6wOVI2QSEQvF2= NU\FUmsxW0GQR1XS
NCI-H1770 M4LaW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jLNmlEPTB;Nj6yNFg4PCEQvF2= NH3OelNUSU6JRWK=
SK-MEL-3 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DacWlEPTB;Nj60NlkyPSEQvF2= MYjTRW5ITVJ?
LB1047-RCC M3LZPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zPeGlEPTB;Nj60O|YzPSEQvF2= NWHwcow3W0GQR1XS
NCI-H446 NEnVeoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTLUWJKSzVyPU[uOlI6OjVizszN M{CxcHNCVkeHUh?=
SW780 NGLhZWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1j6bGlEPTB;Nj63NFE5PSEQvF2= MlvCV2FPT0WU
NEC8 Ml3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTPTWM2OD14Lke2OlMh|ryP M2OxPHNCVkeHUh?=
NOMO-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLLNZBOUUN3ME22Mlc5OTFzIN88US=> NH\qSGxUSU6JRWK=
COLO-668 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTZwOESzPFch|ryP M2rRbnNCVkeHUh?=
MC116 NV3HfY51T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoOyTWM2OD14LkmzPFk4KM7:TR?= M4TBR3NCVkeHUh?=
HCC1937 NHv4PIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rJNWlEPTB;Nj65PVI2OSEQvF2= NG\W[4NUSU6JRWK=
NCI-N87 M3L1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{CzZWlEPTB;Nz6xPVI6OyEQvF2= M2\YUXNCVkeHUh?=
COLO-320-HSR Mn\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTdwMkK3N|gh|ryP NF3YV3lUSU6JRWK=
HCC1806 M3PqZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTdwMk[wOFQh|ryP NV;tRlUxW0GQR1XS
OVCAR-3 MkPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTdwM{OwN|gh|ryP MYTTRW5ITVJ?
NUGC-3 NWPqd|gyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDQTHNjUUN3ME23MlM6Pjl2IN88US=> M2rRTnNCVkeHUh?=
SW1783 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTdwNEOxO|Uh|ryP MoLvV2FPT0WU
GCT MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXj4blZUUUN3ME23MlU3QTB4IN88US=> Mk\oV2FPT0WU
NCI-H2126 MnjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETOTotKSzVyPUeuO|M3OjVizszN NYiyUnZ7W0GQR1XS
MEL-HO NH3wflJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTdwN{ewOVQh|ryP NXHhV5h3W0GQR1XS
CAPAN-1 NWHhe|I{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTdwN{ezOVch|ryP M4PDXnNCVkeHUh?=
SW756 NV7SUpFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrmXGhKSzVyPUeuO|g{OzNizszN NXL6TZlRW0GQR1XS
SKG-IIIa NGSyVmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDkUZJtUUN3ME23MlgyQDl{IN88US=> NI\qUY1USU6JRWK=
HCE-T NInkUJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nsfGlEPTB;Nz64O|c5OyEQvF2= M1XYcHNCVkeHUh?=
Ca-Ski MkfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTdwOUmzPFMh|ryP M2\JSHNCVkeHUh?=
COLO-684 Mmi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRThwMEG4NVgh|ryP M4XJTnNCVkeHUh?=
KYSE-70 MkDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnvTJZKSzVyPUiuNFc4OjlizszN M2rMc3NCVkeHUh?=
TI-73 M{GwWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXxd3hKSzVyPUiuNlU5PTFizszN NHL1cnZUSU6JRWK=
BT-20 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHntRWpKSzVyPUiuNlYxPTJizszN M2XuUHNCVkeHUh?=
MHH-ES-1 MnTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1:1Z2lEPTB;OD61NVg{PCEQvF2= NX;R[HZ1W0GQR1XS
TE-12 NXnwOYx{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mof6TWM2OD16LkW5PVMyKM7:TR?= NEnlXWJUSU6JRWK=
YH-13 MofLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRThwNkGwNFgh|ryP NU\6R4p5W0GQR1XS
SF126 M2\tbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjidJlKSzVyPUiuPFM5PjVizszN MkPMV2FPT0WU
J82 MlruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWOzSoNMUUN3ME24MlkxODN6IN88US=> NE\HSpZUSU6JRWK=
RCC10RGB M2nkW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvrTWM2OD16Lkm5OVYyKM7:TR?= MoXYV2FPT0WU
SK-UT-1 Ml3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jWbWlEPTB;OT6wOFk1PSEQvF2= M1zpfXNCVkeHUh?=
LB2241-RCC NWjVWYxST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGr3T4ZKSzVyPUmuNVkyOzdizszN NFvrflRUSU6JRWK=
LB996-RCC MljCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTlwMUm4PUDPxE1? M{jhOnNCVkeHUh?=
EPLC-272H MlvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDSfooxUUN3ME25MlM4PjV5IN88US=> NHjtN3BUSU6JRWK=
CTV-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DsdmlEPTB;OT61OlU{OiEQvF2= MU\TRW5ITVJ?
HSC-2 NWfrcWJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DpcWlEPTB;OT61O|U2KM7:TR?= MmrzV2FPT0WU
SK-MEL-28 NYfLOXJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTlwNkG4PVMh|ryP M1q3cXNCVkeHUh?=
MMAC-SF NVfzVoVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnyU2RoUUN3ME25MlY5PzVizszN MoWxV2FPT0WU
CP50-MEL-B MljVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTlwN{W3PFIh|ryP NUn2SnR6W0GQR1XS
HT-1080 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HI[mlEPTB;OT63O|c{QSEQvF2= NFrzOGFUSU6JRWK=
HEC-1 M3rFcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjweIxPUUN3ME2xNE4{OzV{IN88US=> MnPsV2FPT0WU
AGS M2PCN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHG2UlhKSzVyPUGwMlM4PCEQvF2= NWjsR2FPW0GQR1XS
GAMG NVXIfnhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\rcGxKSzVyPUGwMlUyPjJizszN NUiyPHUxW0GQR1XS
SW48 Ml\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHZc|ZKSzVyPUGwMlUyQDlizszN M{XHbXNCVkeHUh?=
U031 M1T6XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVL5RYI{UUN3ME2xNE42QTB6IN88US=> NEWzcWdUSU6JRWK=
OVCAR-5 Mn\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTFyLk[0Nlkh|ryP M3\p[nNCVkeHUh?=
SF295 NH;6e2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3QTWM2OD1zMD62O|A1KM7:TR?= MVnTRW5ITVJ?
BHT-101 M2PMbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;vWGlEPTB;MUCuO|E4PyEQvF2= NEX2VY1USU6JRWK=
VMRC-RCZ M36zUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHiwW|lKSzVyPUGxMlMzODFizszN MmDHV2FPT0WU
ACHN MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTFzLkSyNVEh|ryP MYXTRW5ITVJ?
NCI-H526 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInQUW1KSzVyPUGxMlUxPDNizszN MXTTRW5ITVJ?
MN-60 NHXHeFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;TWnRKSzVyPUGxMlU{QSEQvF2= NX3DNYYzW0GQR1XS
NCI-H2291 NEfyXVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnsTWM2OD1zMT61OFY3KM7:TR?= M3zuT3NCVkeHUh?=
SCC-25 MkWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLkTWM2OD1zMT63OVU3KM7:TR?= M3ywTXNCVkeHUh?=
SK-MEL-2 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTFzLke2N|ch|ryP NE\BWXpUSU6JRWK=
SN12C NVnzV4ZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XQRmlEPTB;MUGuPVM2PSEQvF2= M{fpZXNCVkeHUh?=
NCI-H69 M{\NXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFK2W|hKSzVyPUGyMlQzOzRizszN MkP3V2FPT0WU
ME-180 Ml7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jOXmlEPTB;MUKuO|A2PCEQvF2= MkSzV2FPT0WU
MC-IXC NI\sXolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjnXGVHUUN3ME2xNk44PTF6IN88US=> MV3TRW5ITVJ?
NCI-H2347 NEnPSHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTF{Lke2NVQh|ryP Mn60V2FPT0WU
M059J M{TnbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWKzV4ExUUN3ME2xNk44PzJ5IN88US=> MnHkV2FPT0WU
A2058 NWfEW2pHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3FNY9KSzVyPUGyMlg3QDFizszN MkTYV2FPT0WU
VA-ES-BJ Mn\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nsNGlEPTB;MUKuPFc5PSEQvF2= NF;nbpJUSU6JRWK=
Ca9-22 Ml\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTF{Lkm0OVEh|ryP NIfUSGpUSU6JRWK=
KNS-42 MmTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHnTWM2OD1zMj65PVg1KM7:TR?= NF34fYpUSU6JRWK=
LoVo M2nXbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\wdnBpUUN3ME2xN{4zOzF|IN88US=> MYTTRW5ITVJ?
AM-38 M3rG[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7vbo9iUUN3ME2xN{4zPTZ4IN88US=> NW[5RopLW0GQR1XS
NB5 NIizc2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7melVKSzVyPUGzMlM4PTJizszN MYDTRW5ITVJ?
L-363 MnL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTF|LkSwN|Mh|ryP MkDsV2FPT0WU
SK-MEL-30 MkTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGWzdYdKSzVyPUG0MlA3PDVizszN NYPheJI3W0GQR1XS
NCI-H1563 M1jsPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXvSIN7UUN3ME2xOE43ODN7IN88US=> NU\KOJZYW0GQR1XS
NCI-H2228 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rwe2lEPTB;MUSuOlA4PyEQvF2= M3TwRXNCVkeHUh?=
MFM-223 NXfuOYllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvjTWM2OD1zNT6xPFE{KM7:TR?= M{HGdXNCVkeHUh?=
LB831-BLC NXPxVZhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH75UYZKSzVyPUG1MlI4PjdizszN NVzBVYI1W0GQR1XS
SW872 M{m2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrBTWM2OD1zNT6zNFg3KM7:TR?= NUfkUGlFW0GQR1XS
NCI-H522 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfHblNjUUN3ME2xOU4{OzB4IN88US=> NVnXd2szW0GQR1XS
EW-1 MmS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDObY5KSzVyPUG1MlU1PjJizszN M2rJZXNCVkeHUh?=
HN MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzTTWM2OD1zNT61PVQzKM7:TR?= M3PJN3NCVkeHUh?=
SW837 MnHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTkWnJSUUN3ME2xOU44QDR5IN88US=> NUHTO|hSW0GQR1XS
SCC-9 MmrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmf4TWM2OD1zNT64NVE1KM7:TR?= NH;VU|lUSU6JRWK=
MKN7 M{HoRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkKyTWM2OD1zNT65O|MzKM7:TR?= NWXndWxGW0GQR1XS
KYSE-410 NWTJeJBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfwU5REUUN3ME2xOk42QTFizszN Mk\TV2FPT0WU
SK-N-DZ NFznW|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DjSWlEPTB;MU[uOlEyPiEQvF2= NF7XW5dUSU6JRWK=
COR-L105 M4\yUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXQc5dKSzVyPUG2MlY2OjhizszN NX3GSotwW0GQR1XS
LB2518-MEL NYTJWHZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTF4LkizPFkh|ryP M13LUHNCVkeHUh?=
OVCAR-4 NWjhWVNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorLTWM2OD1zNj64PFYzKM7:TR?= NETzbpdUSU6JRWK=
TK10 NF3pc2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmf2TWM2OD1zNj65OFc{KM7:TR?= M3LETXNCVkeHUh?=
KNS-62 MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG[zPZhKSzVyPUG2Mlk4PzdizszN M1XUdXNCVkeHUh?=
RPMI-8866 NWf0blFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rteWlEPTB;MUeuNVc{OiEQvF2= NVeydWMxW0GQR1XS
HuP-T4 Mnf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYr1em5YUUN3ME2xO{4zPDl3IN88US=> NWCzOWtHW0GQR1XS
CGTH-W-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTaTWM2OD1zNz61NlE6KM7:TR?= M2L1V3NCVkeHUh?=
T-24 NWD2TJNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITLV4ZKSzVyPUG3MlU{PDdizszN MVPTRW5ITVJ?
HT-3 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NICwNmVKSzVyPUG3MlU6OTRizszN NUfmR5V4W0GQR1XS
KS-1 Mlm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXnTZhCUUN3ME2xO{43PzNizszN M{PKUXNCVkeHUh?=
NCI-H1792 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;STWM2OD1zNz63PVgh|ryP MV3TRW5ITVJ?
ABC-1 M{DpdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2SwSmlEPTB;MUeuPFE1OSEQvF2= NVjMVWFKW0GQR1XS
BPH-1 M2HwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnzfXBKSzVyPUG4MlE3QDVizszN NWnOZYExW0GQR1XS
A431 NY\1b4ZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVOwdlAyUUN3ME2xPE41OTJ5IN88US=> NGewPIlUSU6JRWK=
T98G M1rRSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfifphKSzVyPUG4MlUyPTdizszN M3r3R3NCVkeHUh?=
BHY MojYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;3RYVWUUN3ME2xPE45PjlizszN NYHTRmNIW0GQR1XS
Capan-2 MnPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7ZZ|lKSzVyPUG4MlkxPzhizszN NHP3fW9USU6JRWK=
MDA-MB-175-VII NGP4Z|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTDW2UzUUN3ME2xPE46OjB7IN88US=> NGDGdXFUSU6JRWK=
CAL-27 NUHk[FJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\6TWM2OD1zOT6wOFg4KM7:TR?= NWnLRmFYW0GQR1XS
AsPC-1 NFzO[21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TrdWlEPTB;MUmuPFY2PyEQvF2= MV\TRW5ITVJ?
KU812 NWjpU2NFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTF7Lkm1O|Mh|ryP MV\TRW5ITVJ?
NCI-H441 Mn3LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHTOmpKSzVyPUKwMlAxOSEQvF2= NHzkdmlUSU6JRWK=
Mewo NHHyWXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkG3TWM2OD1{MD6xNlg5KM7:TR?= NXrBO5dEW0GQR1XS
SK-MEL-24 NU\YR5F{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7DTWM2OD1{MD6xOFc4KM7:TR?= NIXxb4JUSU6JRWK=
NCI-H727 MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;XTWM2OD1{MD6yO|A1KM7:TR?= NXzYbWlRW0GQR1XS
EKVX M17KcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrJTWM2OD1{MD62NFYh|ryP M2P5R3NCVkeHUh?=
RT-112 M4HWbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTJyLk[xNlIh|ryP NXPtSox1W0GQR1XS
CAMA-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13JNGlEPTB;MkCuPVgxOyEQvF2= NUTRXGdVW0GQR1XS
SW900 NHuyU2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mly2TWM2OD1{MT6wNVQ6KM7:TR?= M120TnNCVkeHUh?=
NCI-H23 NHnIcFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTjSXBlUUN3ME2yNU4yOjd5IN88US=> NHPMXmVUSU6JRWK=
SK-PN-DW MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rXZmlEPTB;MkGuNVY1QSEQvF2= MnzxV2FPT0WU
BB30-HNC MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTNTWM2OD1{MT6yO|Q2KM7:TR?= M{jvenNCVkeHUh?=
VM-CUB-1 NFizUXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjp[5dCUUN3ME2yNU4{PTN4IN88US=> NH7mfIxUSU6JRWK=
IST-MEL1 NW\iWoZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LWc2lEPTB;MkGuN|Y6OiEQvF2= M1rmRXNCVkeHUh?=
CTB-1 NXvNS45ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTJzLkS3OVUh|ryP Mmr1V2FPT0WU
LCLC-103H NIDDblhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkP0TWM2OD1{Mj6xOVgzKM7:TR?= M{jBVHNCVkeHUh?=
PANC-03-27 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7UdZNlUUN3ME2yNk42OTZ7IN88US=> MlrKV2FPT0WU
HTC-C3 M{TRUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HjeWlEPTB;MkKuOVU2PSEQvF2= NGLONZBUSU6JRWK=
TE-8 M4r0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUOyO2V[UUN3ME2yN{4zPTZ3IN88US=> NXvUboJRW0GQR1XS
NCI-H292 NILQPXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2n6S2lEPTB;MkWuN|U{PiEQvF2= M3rtVXNCVkeHUh?=
COLO-680N NEH2U4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTJ3Lk[zNlkh|ryP NITxNWtUSU6JRWK=
KYSE-520 NWG1b2pxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHiW5E5UUN3ME2yOU43PDRizszN M2LNdHNCVkeHUh?=
NB10 NFnRdpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfDbIRKSzVyPUK2MlMyOTdizszN NY\Bbot7W0GQR1XS
NCI-H661 NGL2NmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnGTWM2OD1{Nj60O|E{KM7:TR?= MljXV2FPT0WU
GMS-10 NGDPSm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXuTWM2OD1{Nj64OlM5KM7:TR?= NV[2OI95W0GQR1XS
NCI-H2122 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvhTWM2OD1{Nj65PVk5KM7:TR?= M2\wRnNCVkeHUh?=
OVCAR-8 Mm\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXDTWM2OD1{Nz6wOlM5KM7:TR?= NWnaVGpXW0GQR1XS
DJM-1 NGLoOXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDrVoxrUUN3ME2yO{4yPDV2IN88US=> NXjOZ3E5W0GQR1XS
UACC-893 M{TTTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXGTWM2OD1{Nz65PFc5KM7:TR?= NF7u[VRUSU6JRWK=
C8166 MknCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrmTWM2OD1{OD62PVM5KM7:TR?= MlPTV2FPT0WU
NCI-H1693 M3rm[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPETWM2OD1{OD62PVc2KM7:TR?= MkHFV2FPT0WU
TYK-nu NHmwNoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPHTWM2OD1|MD6wN|Q2KM7:TR?= NVHCOJpkW0GQR1XS
SW1710 M1q2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTNyLkGyOkDPxE1? MnHEV2FPT0WU
A375 MorHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH:wd45KSzVyPUOwMlMzPDNizszN MofjV2FPT0WU
HMV-II NFzE[5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTNzLkO1PVIh|ryP M2PqWHNCVkeHUh?=
NCI-H2087 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHFTWM2OD1|MT62N|UzKM7:TR?= NUDBNVBmW0GQR1XS
CAL-54 NYOzRXBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDBeGUyUUN3ME2zNU44OjRzIN88US=> M3TmenNCVkeHUh?=
HCC70 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4r6NWlEPTB;M{KuNVM5PyEQvF2= NUe1V3Z7W0GQR1XS
ES1 NEO3OFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHrTWM2OD1|Mj6zNFYzKM7:TR?= NX\MOGRXW0GQR1XS
NCI-H1355 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfXelY6UUN3ME2zN{4zODRizszN M4rKPHNCVkeHUh?=
CFPAC-1 NFXCNnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPnTWM2OD1|Mz6yN|MzKM7:TR?= MkPvV2FPT0WU
MKN28 NXvLOXFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTJTWM2OD1|Mz6zPFA6KM7:TR?= MoTwV2FPT0WU
HDLM-2 M1i0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXL1dms6UUN3ME2zN{43QTNzIN88US=> M3LOZXNCVkeHUh?=
PANC-10-05 NGjiRXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvodIczUUN3ME2zOE4yODF2IN88US=> MXvTRW5ITVJ?
SAS MofCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLzTWM2OD1|ND60OVY2KM7:TR?= NY\ZT|hmW0GQR1XS
HCC1395 NWLIflJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\2TpFKSzVyPUO0MlcyQDZizszN MnvZV2FPT0WU
8305C NUnBPHg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnyc4JKSzVyPUO1Mlg1OTVizszN NHjYe4VUSU6JRWK=
KM12 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTN4Lke1OFch|ryP MWnTRW5ITVJ?
SW1116 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVv3Rog2UUN3ME2zO{42QTl{IN88US=> MoD0V2FPT0WU
SK-MEL-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYX1eGxSUUN3ME2zPE4{Ozh7IN88US=> M3nBRXNCVkeHUh?=
HCC2218 NES2WHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDH[IJKSzVyPUO4MlY2OTlizszN M17MeHNCVkeHUh?=
T84 NVH6UHBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1[0W2lEPTB;M{iuO|QxQSEQvF2= MVTTRW5ITVJ?
ETK-1 NW\RU2pHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTN7LkCyNkDPxE1? MYPTRW5ITVJ?
COLO-800 NHvOfllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljNTWM2OD1|OT6zPFY5KM7:TR?= M3HxV3NCVkeHUh?=
CAL-12T M3;W[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3juPGlEPTB;M{muOVI5OSEQvF2= NU\pN3RLW0GQR1XS
ACN MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3m1UWlEPTB;NECuOFkyOSEQvF2= NEDVV4FUSU6JRWK=
SJSA-1 NFjHZ4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnYToFKSzVyPUSxMlE2QTZizszN MnvoV2FPT0WU
PSN1 M1;LNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkD4TWM2OD12MT6xO|Q6KM7:TR?= NIXOZXlUSU6JRWK=
D-566MG NFm1eplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTRzLkKwPFYh|ryP NYfYZph[W0GQR1XS
EGI-1 NHHpN2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTR{LkSyPEDPxE1? MXrTRW5ITVJ?
A204 M1r4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHCOYt3UUN3ME20Nk43Ozh6IN88US=> M1nE[3NCVkeHUh?=
Saos-2 NVL6XIxqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXyTWM2OD12Mj64N|Y6KM7:TR?= NGLYfXZUSU6JRWK=
SNU-C2B MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjrT|lKSzVyPUSzMlY5PzhizszN NF64do5USU6JRWK=
HLE MnjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGC3WHRKSzVyPUS0MlA5PTZizszN MWnTRW5ITVJ?
SW1463 MlTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfXfmVwUUN3ME20OE46QTdzIN88US=> MkPHV2FPT0WU
DSH1 NIXoOFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlruTWM2OD12NT6wNFM{KM7:TR?= MlWxV2FPT0WU
MCF7 NXHjWJdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rVbmlEPTB;NEWuOVA2OSEQvF2= M4jXcXNCVkeHUh?=
K5 MoD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIe0VnJKSzVyPUS1Mlk1ODVizszN M2fzN3NCVkeHUh?=
NCI-H358 NHjob|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XxNmlEPTB;NEeuNlE2KM7:TR?= NEDBVWNUSU6JRWK=
NCI-H2030 Ml\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTR5LkKzO|Qh|ryP NF[0dlRUSU6JRWK=
SW948 MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTR5LkS2OEDPxE1? NUnyeGRRW0GQR1XS
BALL-1 NXvwcXh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TlSWlEPTB;NEeuOlE3QCEQvF2= MY\TRW5ITVJ?
TE-9 MnHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfuO3dKSzVyPUS3Mlk2QDFizszN M3PVRXNCVkeHUh?=
SK-N-FI MmH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjIUGFKSzVyPUS4MlA{PThizszN NH;XeZdUSU6JRWK=
KALS-1 Ml7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;TV2lEPTB;NEiuNVI5QSEQvF2= M1O3VnNCVkeHUh?=
HO-1-N-1 NFizeFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDh[lVuUUN3ME20PE44PDR3IN88US=> NFnydFlUSU6JRWK=
NCI-H2452 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHJTWM2OD12OT6xNVUzKM7:TR?= MnXVV2FPT0WU
OC-314 NGLPToNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk[2TWM2OD12OT62PFM1KM7:TR?= MXPTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Affinity determination:

Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research:

[1]

+ Expand
  • Cell lines: SCLC cell lines
  • Concentrations: 0-1 μM
  • Incubation Time: 48 hours
  • Method:

    Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice
  • Formulation: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
  • Dosages: 100 mg/kg/d
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (102.6 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
In vivo Add solvents individually and in order:
5% DMSO+corn oil
7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 974.61
Formula

C47H55ClF3N5O6S3

CAS No. 923564-51-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02520778 Recruiting EGFR Activating Mutation|Recurrent Non-Small Cell Lung Carcinoma|Stage III Non-Small Cell Lung Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer National Cancer Institute (NCI) March 2016 Phase 1
NCT02591095 Active, not recruiting Platinum-resistant or Refractory Ovarian Cancer Centre Francois Baclesse|ARCAGY/ GINECO GROUP|French Cancer Research Hospital Program January 2016 Phase 2
NCT02143401 Recruiting Recurrent Hepatocellular Carcinoma|Solid Neoplasm|Stage IV Hepatocellular Carcinoma National Cancer Institute (NCI) November 2014 Phase 1
NCT02079740 Recruiting Advanced Solid Neoplasm|KRAS Gene Mutation|Metastatic Solid Neoplasm|NRAS Gene Mutation|Recurrent Colorectal Carcinoma|Recurrent Lung Carcinoma|Recurrent Pancreatic Carcinoma|Stage III Colorectal Cancer|Stage III Lung Cancer|Stage III Pancreatic Cancer|Stage IIIA Colorectal Cancer|Stage IIIB Colorectal Cancer|Stage IIIC Colorectal Cancer|Stage IV Colorectal Cancer|Stage IV Lung Cancer|Stage IV Pancreatic Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer National Cancer Institute (NCI) March 2014 Phase 1|Phase 2
NCT01989585 Recruiting Metastatic Melanoma|Recurrent Melanoma|Solid Neoplasm|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma National Cancer Institute (NCI) October 2013 Phase 1|Phase 2
NCT01828476 Completed Prostate Cancer Rutgers, The State University of New Jersey|Rutgers Cancer Institute of New Jersey|National Cancer Institute (NCI)|AbbVie June 2013 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy Navitoclax (ABT-263) | Navitoclax (ABT-263) supplier | purchase Navitoclax (ABT-263) | Navitoclax (ABT-263) cost | Navitoclax (ABT-263) manufacturer | order Navitoclax (ABT-263) | Navitoclax (ABT-263) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID